Anzeige
Mehr »
Login
Samstag, 04.12.2021 Börsentäglich über 12.000 News von 683 internationalen Medien
Unfassbar! New Yorker Investmentbank der ersten Reihe ruft 25-USD-Kursziel aus! +735%
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C2HG ISIN: US18271L1070 Ticker-Symbol:  
NASDAQ
03.12.21
22:00 Uhr
4,470 US-Dollar
-0,490
-9,88 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
CLARUS THERAPEUTICS HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
CLARUS THERAPEUTICS HOLDINGS INC 5-Tage-Chart

Aktuelle News zur CLARUS THERAPEUTICS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrClarus Therapeutics secures $15M capital raise in private placement-
FrClarus Therapeutics Holdings, Inc.: Clarus Therapeutics Announces $15 Million Private Placement1
CLARUS THERAPEUTICS Aktie jetzt für 0€ handeln
MiClarus Therapeutics: Advancing Androgen Replacement And Metabolic Therapies1
DiClarus Therapeutics jumps over 50% after securing new U.S. patents for Jatenzo-
DiClarus Therapeutics Holdings, Inc.: Clarus Therapeutics Announces Issuance of Two New Patents for JATENZO (testosterone undecanoate)1
23.11.MNOV, ESPR and CRXT among after hour movers13
19.11.Clarus Therapeutics Holdings, Inc. - S-8, Securities to be offered to employees in employee benefit plans3
19.11.Clarus Therapeutics Holdings, Inc. - 10-Q, Quaterly Report2
19.11.Clarus Therapeutics' (CRXT) CEO Bob Dudley on Q3 2021 Results - Earnings Call Transcript1
18.11.Clarus Therapeutics reports Q3 results-
18.11.Clarus Therapeutics Holdings, Inc. - 8-K, Current Report-
17.11.Clarus Therapeutics Holdings, Inc.: Clarus Therapeutics to Report Third Quarter 2021 Financial and Operating Results1
16.11.Clarus Therapeutics Holdings, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB1
04.11.Clarus Therapeutics climbs over 50% with 10x average share volume-
26.10.Clarus Therapeutics Holdings, Inc.: Clarus Therapeutics Announces Two Notices of Allowance for Patent Claims Covering JATENZO (testosterone undecanoate)-
14.10.Clarus Therapeutics Holdings, Inc.: Clarus Therapeutics to Present New Real-World Experience Data for JATENZO (testosterone undecanoate) at the 22nd Annual ...1
30.09.Clarus Therapeutics Holdings, Inc. - S-1, General form for registration of securities1
22.09.Clarus Therapeutics Holdings, Inc.: Clarus Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference1
20.09.Clarus Therapeutics Holdings, Inc. - 8-K, Current Report1
16.09.Clarus Therapeutics, McGill University Ink Licensing Pact For Rare CoQ10-Associated Conditions2
Seite:  Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1